Verastem, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Securities Trading Plan of Directors and Executive Officers
On September 2, 2026, Eric K. Rowinsky, MD, a member of the board of directors, adopted a Rule 10b5-1 plan providing for the sale of up to 82,874 shares of the Company’s common stock. Pursuant to this plan, Dr. Rowinsky may sell shares of common stock beginning on December 1, 2026, subject to the terms of the plan, and the plan will terminate on or prior to December 24, 2028. The trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.